公开(公告)号：US10130714B2

公开(公告)日：2018-11-20

申请号：US13836356

申请日：2013-03-15

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Jim-Min Fang ,  Kung-Cheng Liu ,  Jia-Tsrong Jan ,  Yih-Shyun E. Cheng ,  Ting-Jen R. Cheng

IPC: A61K31/351 ,  C07D309/28 ,  A61K47/55 ,  A61K47/48

Abstract: Novel dual-targeted, bifunctional anti-influenza drugs formed by conjugation with anti-inflammatory agents are disclosed. Exemplary drugs according to the invention include caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1), ZA-7-CA-amide (7) and ZA-7-Nap (43) for simultaneous inhibition of influenza virus neuraminidase and suppression of proinflammatory cytokines. Synthetic methods for preparation of these enhanced anti-influenza conjugate drugs are provided. The synthetic bifunctional ZA conjugates act synergistically towards protection of mice lethally infected by H1N1 or H5N1 influenza viruses. The efficacy of ZA-7-CA, ZA-7-CA-amide and ZA-7-Nap conjugates is much greater than the combination therapy of ZA with anti-inflammatory agents.

公开(公告)号：US20180280942A1

公开(公告)日：2018-10-04

申请号：US15940122

申请日：2018-03-29

Applicant: ACADEMIA SINICA ,  National Taiwan University

Inventor： Kuei-Hsien CHEN ,  Indrajit SHOWN ,  Wei-Fu CHEN ,  Li-Chyong CHEN LIN

IPC: B01J27/04 ,  B01J21/18 ,  B01J35/00 ,  B01J35/08 ,  B01J35/02 ,  B01J37/04 ,  B01J37/10 ,  B01J37/34 ,  B01J19/12 ,  C01B3/04 ,  C01B13/02 ,  C07C45/00 ,  C07C1/02

Abstract: Disclosed herein are carbon doped tin disulphide (C—SnS2) and other SnS2 composites as visible light photocatalyst for CO2 reduction to solar fuels. The in situ carbon doped SnS2 photocatalyst provide higher efficiency than the undoped pure SnS2. Also disclosed herein are methods for preparing the catalysts.

公开(公告)号：US10086054B2

公开(公告)日：2018-10-02

申请号：US14392341

申请日：2014-06-26

Applicant: ACADEMIA SINICA

Inventor： Chi-Huey Wong ,  Chung-Yi Wu ,  Hong-Yang Chuang ,  Chien-Tai Ren

IPC: C07H15/04 ,  A61K39/00 ,  A61K39/385 ,  A61K31/7028 ,  C07K14/47 ,  A61K49/00 ,  C07H15/10 ,  C07H15/14

Abstract: Described herein are synthetic glycan conjugates, immunogenic compositions thereof, vaccines thereof, and kits thereof. The present invention further provides methods of using the synthetic glycan conjugates, immunogenic compositions, or vaccines thereof to treat and/or prevent and/or diagnose proliferative diseases such as cancer. The provided glycan conjugate comprises a carrier and a glycan moiety of Formula (I-i) or Formula (I-ii): (structurally represented).

公开(公告)号：US10036033B2

公开(公告)日：2018-07-31

申请号：US14828842

申请日：2015-08-18

Applicant: Academia Sinica

Inventor： Tuan-Hua David Ho ,  Wan-chi Lin ,  Kuan-Ying Huang

IPC: C12N15/87 ,  C12N15/82

CPC classification number: C12N15/8267

Abstract: The present invention relates to a method for inhibiting sprouting, particularly pre-harvest sprouting, in plant seeds, by introducing a polynucleotide encoding a FCA protein into the plant.

公开(公告)号：US10034848B2

公开(公告)日：2018-07-31

申请号：US14925007

申请日：2015-10-28

Applicant: Academia Sinica

Inventor： Yi-Ping Hsueh

IPC: A61K31/00 ,  A61K31/198

CPC classification number: A61K31/198 ,  A61K31/00

Abstract: Disclosed herein is a method for increasing the dendritic spine formation or dendritic spine density in a subject, who is affected by a dendritic spine defect caused by the impairment in neurofibromin (NF1 protein), valosin-containing protein (VCP), atlastin-1 (ATL1), or superoxide dismutase 1 (SOD1). Accordingly, also disclosed herein is a method for treating a subject having or suspected of having a synaptopathy caused by the impairment in NF1, VCP, ATL1, or SOD1.

公开(公告)号：US20180201672A1

公开(公告)日：2018-07-19

申请号：US15322788

申请日：2015-06-30

Applicant: Wen-Hwa Lee ,  Academia Sinica

Inventor： Wen-Hwa Lee ,  Jin-Yuh Shew ,  Che Ma ,  Chia-Lin Chen ,  Wen-Hsin Lee ,  Chun-Kai Huang ,  Heng-Hsiung Wu

IPC: C07K16/24 ,  A61P35/00 ,  C12N15/113 ,  A61K39/395 ,  A61K45/06 ,  C07K14/715

Abstract: Methods and compositions for treatment and therapy of cancer are provided. Specifically, antagonists specific for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B are provided. Potent neutralizing antibodies specific for IL-17RB and methods for their manufacture and use are disclosed. The invention also relates to antisense, RNAi and shRNA compositions for the prevention and treatment of cancer, in particular breast cancer and pancreatic cancer.

公开(公告)号：US10016748B2

公开(公告)日：2018-07-10

申请号：US14509509

申请日：2014-10-08

Applicant: Academia Sinica

Inventor： Ming-Hsi Chiang ,  Yu-Chiao Liu ,  Kai-Ti Chu

IPC: B01J31/22 ,  C25B1/02 ,  C07F15/02

CPC classification number: B01J31/226 ,  B01J2231/60 ,  B01J2531/842 ,  C07F15/02 ,  C25B1/02 ,  H01M8/0656

Abstract: This invention relates to an iron-sulfur complex that is capable of efficiently catalyzing formation of hydrogen, and a method for producing hydrogen using the complex as a catalyst. The iron-sulfur complex provided herein comprises: a structure of formula (I) wherein the ligands L1 to L3, L5 and L6 and the groups X1 to X3 are each selected from the group consisting of alkyl, alkenyl, alkynyl and aryl that are substituted or unsubstituted, hydroxyl, carbonyl, aldehyde, and so on; L4 is a bridging ligand selected from the group consisting of hydroxyl, carbonyl, and so on; and the symbol “z” means the charge, which is an integer with the range of −3 to +2. X1 and X2 may join together to form a bridging group between the two sulfur atoms. X3 may alternatively be a vacant site.

公开(公告)号：US10005847B2

公开(公告)日：2018-06-26

申请号：US14723181

申请日：2015-05-27

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Chung-Yi Wu

IPC: C07K16/32 ,  C07K16/40 ,  A61K31/517 ,  A61K39/395 ,  C07K16/28 ,  C12P21/00

CPC classification number: C07K16/40 ,  A61K31/517 ,  A61K39/3955 ,  C07K16/283 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/92 ,  C12P21/005 ,  C12Y302/01 ,  C12Y302/01051

Abstract: The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：US09982041B2

公开(公告)日：2018-05-29

申请号：US14599174

申请日：2015-01-16

Applicant: Academia Sinica

Inventor： Chi-Huey Wong ,  Tsui-Ling Hsu ,  Yi-Wei Lou ,  Chih-Wei Lin ,  Shih-Chi Yeh ,  Chung-Yi Wu ,  Han-Chung Wu

IPC: C07K16/18 ,  G01N33/574 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/734 ,  C07K2317/92 ,  G01N33/57407 ,  G01N33/57492 ,  G01N2800/52

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer.

公开(公告)号：US09976146B2

公开(公告)日：2018-05-22

申请号：US15312667

申请日：2015-05-29

Applicant: Academia Sinica

Inventor： Chung-Hsuan Chen ,  Bai-Ling Lin ,  Chin-Yu Wang

IPC: C12N15/115 ,  A61K47/48

CPC classification number: C12N15/115 ,  A61K47/55 ,  C12N2310/16 ,  C12N2310/315 ,  C12N2310/3517 ,  C12N2320/13 ,  C12N2320/31 ,  C12N2320/32

Abstract: Disclosed herein is an aptamer targeting a MHC-presented peptide and its uses thereof. The MHC-presented peptide is expressed in various cancer cells; therefor, the aptamer of the disclosure is useful as a bio-tool to label and/or treat peptide-presenting cancer cells. Also disclosed herein is a pharmaceutical composition containing the aptamer.